

Index

- A**
- A site, 2–3
 - ABCE1, 65–66, 74, 97, 115, 157, 285
 - eRF1 interactions, 70–71
 - reinitiation of translation, 76–77
 - ribosomal splitting mechanism, 71–72
 - structure, 70
 - ABCF1, 205
 - AD. *See* Alzheimer's disease
 - ADAR1, 213
 - AdoCbl, 305
 - AEV. *See* Avian encephalomyelitis virus
 - Ago1, 417
 - Ago2, 267, 271
 - AID. *See* Auxin-induced degron
 - AIRAP, 153
 - AKT, 479–480
 - ALKBH5, 206–207
 - ALS. *See* Amyotrophic lateral sclerosis
 - ALYREF, 202, 204
 - Alzheimer's disease (AD), 435, 480
 - AMPK, 339, 348, 373, 377, 384, 452
 - Amyotrophic lateral sclerosis (ALS), RAN translation, 250–252
 - ANGEL1, 265
 - ANGEL2, 265
 - Apaf-1, 236
 - APP, 480
 - Arc, 382
 - ArfA, 110
 - Argonaute proteins, 317–320
 - Ascl1, 127
 - ASDs. *See* Autism spectrum disorders
 - ASFV, 452
 - Ataluren, 75
 - ATF4, 35, 37, 357, 359–360, 396–397
 - ATF4*, 129, 363, 365
 - ATF5*, 363
 - ATXN8*, 251
 - AUF1, 237, 271
 - Autism spectrum disorders (ASDs), 434–435
 - Auxin-induced degron (AID), 193
 - Avian encephalomyelitis virus (AEV), 233
- B**
- BACE1, 240
 - bcd*, 412–413
 - BCL-2, 470, 477
 - BDNF, 382
 - β -Actin, 427
 - β -Catenin, 381
 - BiP, 236, 358
 - BipA, 109
 - BMPR2, 364
 - Bovine viral diarrhea virus (BVDV), 271
 - BRAF, 480
 - Brat, 417
 - BRCA1, 401, 472
 - Bru, 413
 - BVDV. *See* Bovine viral diarrhea virus
- C**
- CAF1, 265
 - Calmodulin, 384
 - CAMKII, 427, 432
 - CaMV. *See* Cauliflower mosaic virus
 - Cancer
 - eIF4E phosphorylation in metastasis, 382
 - oncogenic signaling, 399–400
 - ribosome features, 400
 - translation control
 - cancer stem cells, 402
 - consequences of deregulation
 - angiogenesis, 400–401
 - apoptosis, 400
 - oncogenic advantages, 401
 - proliferation, 400
 - stress responses, 401
 - deregulation
 - eIF3, 397
 - eIF4F complex formation, 395–396
 - elongation, 397–398
 - termination, 398
 - ternary complex formation, 396–397
 - immune cells, 402
 - overview, 393–394
 - therapeutic targeting, 472–473
 - untranslated region changes in length and composition, 398–399
 - Cap-independent translation element (CITE), 238–239, 452
 - Caprin1, 344
 - Cauliflower mosaic virus (CaMV), 240
 - Cbf5, 200
 - CCR4, 265, 271–272, 323–324, 326–329, 414
 - CDK11, 383
 - CDKN1A*, 363
 - CDKN2A*, 472

Index

- CDR1as, 214–215
CERT, 401
CHOP, 129, 360–361
Chronic myeloid leukemia (CML), 474
Circular RNA
 detection, 215
 functional overview, 215
 prospects for study, 224
 regulation of translation, 215–216
 synthesis, 213–214
 translation, 216–219
CITE. *See* Cap-independent translation element
Classic swine fever virus (CSFV), 116
CML. *See* Chronic myeloid leukemia
CNBP, 253
CNOT1, 203, 271, 324
CNOT8, 291
CPEB, 343, 434
CPEB β , 413
CR5, 56
CREB, 430
CReP, 358–359, 472, 480
CReP, 363–364
Cricket paralysis virus (CrPV), 116–117, 177, 446
CrPV. *See* Cricket paralysis virus
CSFV. *See* Classic swine fever virus
CXTE, 241
CYFIP1, 382
Cytomegalovirus, 448, 452, 455–456
- D**
- DCP1, 266, 291, 326, 344
DCP2, 266, 291, 344
DCPS, 267
DDX6, 266, 270–272, 326–329, 349
Ded1, 127, 147–148
DENR, 65, 72, 76
DENV, 450, 454, 456
Development, translational control
 embryo development
 mRNA localization, 410–414
 translation efficiency and mRNA decay,
 414–415
 overview, 409–410
 prospects for study, 418–419
 stem cell maintenance and differentiation,
 415–418
DGCR8, 316
DHH1, 270, 272
DHX29, 114
DHX34, 290
N⁶,2'-O-dimethyladenosine, 202
DIS3L2, 267, 274
DNAJC3, 365
Dom34, 134, 272, 286
DPH genes, 49
DUSP6, 326
DX3, 349
- E**
- EBV. *See* Epstein–Barr virus
EDC proteins, 266, 326, 344
eEF1A, 47–49, 67, 69, 88, 155, 383, 431
eEF1B, 48–49, 155, 383, 431
eEF2, 49–50, 155, 383, 431–433
eEF2K, 50, 378, 384–385, 432–434, 436, 453
eEF3, 50
EF-G, 55, 87, 89, 93–94, 97, 108–109, 172, 176
EF-P, 47, 50–52, 87, 91–92
EF-Tu, 69, 87–89, 108
Egl, 412
eIF1, 33, 72, 115, 146, 149–152, 233
eIF1A, 27, 33–35, 45, 72, 115, 132, 146, 149–152, 234, 285
eIF2, 4–5, 116, 146, 152, 206, 285, 372, 445. *See also*
 Ternary complex
 activation, 26–27
 GTP hydrolysis and factor release, 34
 therapeutic targeting, 480–482
eIF2A, 13, 35, 129, 233, 483
eIF2 α kinases. *See also specific kinases*
 cancer, 396–397
 integrated stress response
 pathology, 364–365
 therapeutic targets, 365–366
 memory switch, 428–430
 preferential translation
 ribosome bypass, 360–363
 stress type effects, 363–364
 prospects for study, 366
 stress granules, 340–341, 343, 347, 349
 therapeutic targeting, 481–482
 translational control, 355–357
 types activated by stress, 357–359
 upstream open reading frames in integrated stress
 response translational control, 359–360
EIF2AK1, 15
EIF2AK2, 15
EIF2AK3. *See* PERK
eIF2B, 5, 24, 26–27, 36, 146, 364–365, 375, 445, 471, 481
eIF2D, 13, 65, 72, 76–77, 233
eIF3, 27–31, 34, 72, 76, 115, 146, 151, 158, 204, 217, 218,
 285, 375, 382–383, 396–397, 450
eIF3H, 383
eIF4A, 24, 30–32, 36, 127, 148–150, 324, 327–329,
 377–378, 395, 399, 447, 451, 477–479
eIF4A3, 290, 292
eIF4B, 30–32, 148–149, 382, 386, 478
eIF4E, 5, 24, 30–31, 76, 192, 204, 272, 324–326, 360, 374,
 379–382, 386, 395–396, 401, 412–413,
 434–435, 447, 450–451, 470, 472–477
eIF4E-binding proteins, 5, 30–31, 36–37, 148, 375–376,
 396, 417, 431
eIF4F, 17, 31, 72, 146–152, 204, 241, 395, 397–399, 447, 450,
 452, 470–472, 475
eIF4G, 17, 24, 30–32, 36, 127, 147–148, 158, 216, 325–326,
 376, 379–380, 382–383, 396, 413, 434,
 447–448, 452, 470, 475–477, 479–480

- eIF5, 26, 28, 30, 32–36, 115, 146, 151–153, 397, 471
eIF5A, 13, 47, 50–53, 74, 91–92, 132, 155, 398
eIF5B, 35, 116, 234, 480
EJC. *See* Exon junction complex
Elongation, translation
 eukaryotes
 codon optimality in regulation, 153–155
 elongation factors, 48–53, 155–156
 overview, 45–48, 153
 prokaryotes
 decoding, 87–90
 peptide bond formation, 90–92
 protein folding, 94–95
 translocation, 92–94
 translocation and recoding, 94
EMCV. *See* Encephalomyocarditis virus
EMT. *See* Epithelial-to-mesenchymal transition
Encephalomyocarditis virus (EMCV), 231, 233, 344, 450
Epithelial-to-mesenchymal transition (EMT),
 381–382, 399
Epitranscriptome
 differential mRNA modification, 206–207
 $N^6,2'$ -*O*-dimethyladenosine, 202
 5-hydroxymethylcytidine, 202
 innate immunity studies, 205–206
 N^1 -methyladenosine, 201
 N^6 -methyladenosine, 199–200, 204–205
 2'-*O*-methylation of ribose, 201–202
 5-methylcytidine, 202
 overview, 199
 prospects for study, 207–208
 pseudouridine, 200–201, 204
 reading, 202–203
 translation impact
 direct effects, 204–205
 indirect effects, 203–204
EPRS, 363
Epstein–Barr virus (EBV), 455, 457
eRF1, 65–71, 74–75, 77, 158, 285–286, 288
eRF3, 65–71, 74, 158, 286, 288, 290
Exon junction complex (EJC), 214, 273

F
FASTK, 343
FGDE, 344
5MP1, 397
5MP2, 397
FKBP12, 376
FLJ21870, 220
FLNA, 358
FLOSS. *See* Fragment length organization similarity score
Fluorescence resonance energy transfer (FRET)
 conformational changes during prokaryotic translation,
 171–173
 ribosome studies, 108–109
Fluorescent noncanonical amino acid tagging (FUNCAT),
 187–188
FMDV. *See* Foot and mouth disease virus
FMRP, 189, 340, 343, 345, 382, 433–434
Foot and mouth disease virus (FMDV), 233
4EGI-1, 475–477
4EHP, 326–327
4E-T, 326–327
FOXMI, 207
Fragile X tremor ataxia syndrome (FTXAS), RAN
 translation, 252, 255–256
Fragment length organization similarity score
 (FLOSS), 222
FRET. *See* Fluorescence resonance energy transfer
Frontotemporal dementia (FTD), RAN translation,
 250–252
FTD. *See* Frontotemporal dementia
FTO, 206, 240
FTXAS. *See* Fragile X tremor ataxia syndrome
FUNCAT. *See* Fluorescent noncanonical amino acid tagging
FXR1, 340, 343–345

G
G3BP, 344–345, 347–348
G3BP1, 218
GADD34, 358–359, 428, 435, 472, 480
GADD34, 361–363
GCN1, 359
GCN2, 15, 341, 357–359, 364–365, 428, 446, 471, 473, 482
GCN4, 35, 37
GIGYF2, 324–327
glsS, 305–306
grk, 412–413
GSK, 365
GSK2606414, 482
Guanabenz, 480
GW182, 321–324, 344

H
HaloTag, 188–189
Hbs1, 134, 272
HBS1L, 286
HCV. *See* Hepatitis C virus
HD. *See* Huntington's disease
Heme-regulated inhibitor (HR1), 15
Hepatitis C virus (HCV), 116–117, 233–234, 236,
 270–271, 341, 446, 456, 480
Herpes simplex virus-1 (HSV-1), 447–448,
 450–452, 460
HHT. *See* Homoharringtonine
HIF1 α , 401
Hippuristanol, 478–479
HIV. *See* Human immunodeficiency virus
hnRNP, 236
Homoharringtonine (HHT), 474
HR1. *See* Heme-regulated inhibitor
HRCR, 215
HRI, 428, 446, 472, 481
HRSP12, 267
Hsp70, 206, 240, 341

Index

- HSV-1. *See* Herpes simplex virus-1
HTT, 252
Human immunodeficiency virus (HIV), 451
Huntington's disease (HD), RAN translation, 252–253
HuR, 271
5-Hydroxymethylcytidine, 202
- I**
- IER3IP1, 365
IF1, 84–86
IF2, 84–86, 171
IF3, 84–86, 176
IFIT, 457
IGF2BP1, 218
Initiation, translation
 alternative pathways in eukaryotes, 35–36
 AUG recognition, 32–34
 80S initiation pathway regulation, 36–37
 messenger RNA recruitment and scanning, 30–32
 noncanonical initiation. *See also* Internal ribosome entry site
 cap-independent translation elements, 238–239
 N⁶-methyladenosine, 238, 240
 prospects for study, 241–242
 ribosomal shunting, 240–241
 translation initiator of short 5'UTR, 241
 overview
 eukaryotes, 23–26, 144–146
 prokaryotes, 84–87
 preinitiation complex formation
 eIF promotion of ternary complex binding to ribosome 40S subunit, 27–29
 IF2 activation, 26–27
 multifactor complex, 29–30
 ternary complex formation, 26–27
 prospects for study, 37–38
 scanning, 149–150, 152
 60S subunit joining, 34–35
 start codon recognition
 kinetics, 150–152
 regulation, 152–153
Integrated stress response (ISR)
 pathology, 364–365
 therapeutic targets, 365–366
 upstream open reading frames in translational control, 359–360
Integrated stress response inhibitor (ISRIB), 341, 430
Interferon, 444–445, 457
Internal ribosome entry site (IRES), 35, 49–50, 105, 177, 216, 218
 classification of virus sites, 231–234
 Dicistroviridae IGR translation initiation mechanism, 234–235, 453
 hepatitis C virus, 270–271
 history of study, 13–14
 identification, 237–238
 imaging, 110
 initiation and translocation mediation, 116–117
 mammalian mRNA sites, 235–236
 overview, 229–231
 RAN translation in neurological disease
 overview, 256–257
 RNA-binding proteins, 257–258
 trans-acting factors, 236–237
IRE-1, 267
IRES. *See* Internal ribosome entry site
ISR. *See* Integrated stress response
ISRIB. *See* Integrated stress response inhibitor
ISRIB-A1, 481
ITAE, 231, 236, 271
- K**
- KHSRP, 237
KLF4, 207, 272
KRAS, 399–400
KSHV, 447–448, 450–451, 455, 457
Ksp1, 383
- L**
- LARP1, 16, 379, 386
Ligatin. *See* eIF2D
lncRNA. *See* Long noncoding RNA
Long noncoding RNA (lncRNA)
 annotation, 219–220
 prospects for study, 224
 regulation of translation, 220
 short open reading frames, 221–222
 translated micropeptide function, 222–224
 translation, 220–221
Long-term potentiation. *See* Memory
LSM14, 266
LSU- α , 111
LSU- β , 111
LY2275796, 474–475
- M**
- MAGOH, 292
MAPK. *See* Mitogen-activated protein kinase
MAPKAP2, 345
Maternal-to-zygotic transition (MZT), 316, 410–411, 414
MAVS. *See* Mitochondrial antiviral signaling protein
MBNL, 250
MCL-1, 477
MCPIP1, 267
MCT1, 65, 72, 76–77
MDA5, 348, 447
MDM2, 399
Mei-P26, 417–418
Memory, translational control
 dendritic versus somatic protein synthesis, 426–427
 eEF2K regulation of elongation, 432–434
 eIF2 α kinases, 428–430
 general versus specific protein synthesis, 426
 late long-term potentiation and synaptic tagging, 427

- mTORC1 role, 430–431
 - overview, 425–426
 - presynaptic versus postsynaptic protein synthesis, 427–428
 - therapeutic targeting, 473
 - MERS. *See also* Middle East respiratory syndrome
 - Messenger RNA (mRNA)
 - decay. *See also* Nonsense-mediated mRNA decay
 - cotranslational decay
 - DDX6 regulation, 271–272
 - hepatitis C virus, 270–271
 - overview, 268–270
 - protein–RNA interactions with 5'UTR, 271
 - decapping, 265–266
 - embryo development, 414–415
 - endonucleolytic decay, 267–268
 - exoribonucleolytic decay, 266
 - impact of 3'UTR, 273–274
 - nonstop decay, 273–274
 - open reading frame impact on mRNA stability
 - codon optimality/translational velocity of decay, 272
 - exon junction complex, 273
 - no-go decay, 272–273
 - overview, 263–265
 - poly(A) tail deadenylation/removal, 263, 265
 - prospects for study, 274
 - epitranscriptome. *See* Epitranscriptome
 - levels and protein synthesis, 5
 - recruitment and scanning, 30–32
 - structure, 5
 - therapeutic targeting of eIF4F activation, 470–471
 - TOP mRNAs and translation regulation, 378–380
 - virus modifications, 456–457
 - N¹-Methyladenosine, 201
 - N⁶-Methyladenosine, 199–200, 204–205, 238, 240, 456–457
 - 5-Methylcytidine, 202
 - METTL3, 204–207
 - MFC. *See* Multifactor complex
 - MicroRNA
 - Argonaute proteins
 - loading, 317–318
 - microRNA interactions in target recognition, 319–320
 - embryo development translational control, 414–415
 - functional overview, 315–316
 - RNA-induced silencing complex
 - functional interactions in, 3'UTRs, 320–321
 - overview, 319
 - synthesis, 316–317
 - translational repression
 - CCR–NOT complex link with eIF4A, 327–329
 - DDX6 role, 326
 - 4EHP role, 326–327
 - 4E-T role, 326–327
 - GW182-interacting proteins
 - deadenylase complexes, 323–324
 - GIGYF2, 324
 - overview, 321
 - PABP, 321–323
 - initiation factor dissociation from mRNAs, 325–326
 - mechanisms, 324–325, 328
 - prospect for study, 329
 - Middle East respiratory syndrome (MERS), 447
 - Mitochondrial antiviral signaling protein (MAVS), 130
 - Mitogen-activated protein kinase (MAPK), mTORC1 signaling, 374–375
 - MLN51, 273, 292
 - MMP3, 382
 - MNK1, 147, 374, 376, 380, 382, 434, 470
 - MNK2, 376, 380, 471
 - mRNA. *See* Messenger RNA
 - mTOR, 16, 348, 372, 377–378, 402, 416, 435
 - mTORC1, 385
 - memory role, 430–431
 - signaling, 372–374
 - translation regulation through phosphorylation, 374–378
 - mTORC2, 372
 - Multifactor complex (MFC), 43S PIC formation, 29–30
 - Muscleblind, 213
 - MYC, 472, 477
 - Myotonic dystrophy, RAN translation, 250–251, 257
 - MZT. *See* Maternal-to-zygotic transition
- N
- Nanog, 206–207
 - Nanos, 415, 418
 - NCU01977, 308
 - NF- κ B. *See* Nuclear factor- κ B
 - NGD. *See* No-go decay
 - NMD. *See* Nonsense-mediated mRNA decay
 - NMR. *See* Nuclear magnetic resonance
 - NMT1, 308
 - NoBody, 223
 - No-go decay (NGD), 57, 272–273
 - Nonsense-mediated mRNA decay (NMD), 57, 67, 158, 269
 - cancer, 398
 - degradation of mRNA, 290–291
 - inducers
 - exon junction complex, 292–293
 - long 3'UTRs, 293
 - overview, 291–292
 - prospects for study, 293–294
 - inefficient translation termination linkage, 286–287
 - overview, 283–284
 - UPF1 role
 - mechanism, 288
 - overview, 287–288
 - phosphorylation regulation, 288
 - UPF2 role, 290
 - UPF3 role, 290
 - Nonstop decay (NSD), 273–274
 - NORAD, 220

Index

- NOT1, 265
NPH-II, 30
NS1, 453
NSC119889, 480
NSC119893, 480
NSD. *See* Nonstop decay
Nuclear factor- κ B (NF- κ B), 357, 450, 480
Nuclear magnetic resonance (NMR), 167
NUDT3, 266
NUDT16, 266
NXF1, 257
NYN, 294
- O**
- OAS, 446, 460
Oct4, 206
ODC. *See* Ornithine decarboxylase
Omacetaxine mepesuccinate, 474
OPHN1, 430
Orb, 413
Ornithine decarboxylase (ODC), 470
osk, 412–413
- P**
- P1, 454
P2, 454
p53, 399–400
PABP. *See* Poly(A)-binding protein
PABPC1, 338
PAH. *See* Pulmonary arterial hypertension
PAN2, 265, 323–324
PAN3, 265, 323–324, 326
PAN GU, 414–415
PARN. *See* Poly(A) ribonuclease
PAT1, 270
Pateamine A, 477–478
PATL1, 266
PB. *See* Processing body
PCBP2, 218, 231, 236
PDCD4, 148, 386, 396, 399, 471
PELO, 286
Peptidyl-transferase center (PTC), 153
PERK, 15, 341, 357–358, 364–365, 428, 430, 435, 446, 472–473, 480–482
PGK1, 269
PI3K, 472
PIC. *See* Preinitiation complex
PIKK, 416
PKI, 50, 117
PKM, 427
PKR. *See* Protein kinase R
PKZ, 5
PNCR2, 267
PNRC2, 291
Poliovirus, 231
Poly(A) ribonuclease (PARN), 265
Poly(A)-binding protein (PABP), 66, 73–74, 147, 286–287, 321–326, 379, 448, 450, 452
POP2, 265
PP1, 472
Preinitiation complex (PIC)
AUG recognition and conformational change, 32–34
cancer, 397
formation
eIF promotion of ternary complex binding to ribosome 40S subunit, 27–29
eIF2 activation, 26–27
multifactor complex, 29–30
ternary complex formation, 26–27
imaging, 114
messenger RNA recruitment
accommodation of complex on mRNA, 149
eIF4F complex in mRNA selection, 147–148
regulation of complex availability, 146–147
overview, 2, 24
PRF. *See* Programmed ribosomal frameshifting
prfB, 55
Processing body (PB)
condensation, 343–344
overview, 337–339
pathology, 347–348
phase transition concept in formation, 345–347
prospects for study, 348–349
translational control, 344–345
Programmed ribosomal frameshifting (PRF), 53–57, 457–458
Protein kinase R (PKR), 15, 341, 343, 347–348, 357, 396, 428, 430, 435, 445–447, 460, 472, 481–482
PRRSV, 457
PSEN1, 480
Pseudouridine, 200–201, 204
P site, 2–3, 24, 47, 52, 84–85, 92
PTBP1, 293
PTC. *See* Peptidyl-transferase center
PTV-1, 233
PUF proteins, 273
Pulmonary arterial hypertension (PAH), 364
Pum, 418
Pumilio1, 220
- R**
- Rabies virus, 447
RACK1, 127, 347, 453
RAN translation. *See* Repeat-associated non-ATG translation
Recoding
cis-acting factors
flat elements, 53–54
topological features, 54–55
definition, 53
functional outcomes, 56–57
kinetic traps as drivers, 53
prokaryotes, 94
trans-acting factors

- nucleic acids, 56
 - proteins, 55–56
 - small molecules, 55
 - Recycling. *See* Ribosome
 - Reinitiation, translation
 - mobility of 80S ribosomes, 77
 - overview, 75–76
 - regulation
 - initiation factors, 76
 - reinitiation factors, 76–77
 - Repeat-associated non-ATG (RAN) translation, 18, 36, 38
 - amyotrophic lateral sclerosis, 250–252
 - discovery in neurological disease, 250–252
 - fragile X tremor ataxia syndrome, 252, 255–256
 - frontotemporal dementia, 250–252
 - Huntington's disease, 252–253
 - internal ribosome entry sites
 - overview, 256–257
 - RNA-binding proteins, 257–258
 - mechanisms in neurological diseases
 - cap-dependent initiation across CGG repeats, 255–256
 - prospects for study, 258
 - repeat length and repeat sequence, 254–255
 - RNA hairpins and G-quadruplexes, 255
 - myotonic dystrophy, 250–251, 257
 - spinocerebellar ataxia, 250–251, 253
 - toxicity of proteins, 253–254
 - Reticulocyte, history of translational control studies, 15
 - RF1, 70, 75, 95–96, 176
 - RF2, 55–56, 70, 75, 95–96, 110, 176
 - RF3, 95–96, 176
 - Rheb, 372
 - Ribosomal S6 kinases, 374, 385–396, 471
 - Ribosome. *See also* Preinitiation complex
 - cancer features, 400
 - cryoelectron microscopy and imaging studies
 - eubacteria, 107–110
 - initiation in eukaryotes, 113–117
 - overview, 106
 - protozoa, 110–112
 - yeast, 110
 - fluorescence microscopy, 190–191
 - profiling
 - expanded proteome annotation, 130–131
 - footprints of elongation, 131–134
 - gene-specific translation, 125–127
 - limitations, 378
 - molecular mechanisms of control, 127–128
 - noncanonical translation, 128–130
 - overview, 123–124
 - prospects, 134–135
 - termination of translation, 133
 - translation in vivo, 124–125
 - recycling
 - ABCE1
 - splitting of ribosomes, 71–72
 - structure, 70
 - kinetics, 157–158
 - overview in eukaryotes, 65–66, 284–285
 - prokaryotes, 97
 - RNA release, 72
 - translation termination coupling with recycling in
 - prokaryotes, 176
 - shunting, 240–241
 - subunit joining in translation initiation, 34–35
 - Ribosome release score (RRS), 222
 - Riboswitch
 - eukaryotic translation regulation by splicing, 308, 310
 - overview, 301–303
 - prospects for study, 310–312
 - ribozyme regulation of translation by small molecules, 305–308
 - translation control, 303–305
 - Rift Valley fever virus (RVFV), 446
 - RIG-I, 348, 447
 - RIPK1, 482
 - RISC. *See* RNA-induced silencing complex
 - RLAT-1, 381
 - Rli1, 157
 - RNA polymerase (RNAP), 84
 - RNA-induced silencing complex (RISC), 267, 319–321
 - RNAP. *See* RNA polymerase
 - RNase L, 267–268, 348
 - RNH1, 267
 - Rocaglates, 479
 - Rous sarcoma virus (RSV), 293
 - RPL5, 400
 - RPL7, 454
 - RPL11, 400
 - RPL18, 454
 - Rpl24, 416
 - RPL40, 453
 - RRF, 97
 - RRS. *See* Ribosome release score
 - RSK2, 347, 432
 - RSV. *See* Rous sarcoma virus
 - RVFV. *See* Rift Valley fever virus
- ## S
- S6, 374, 385–396
 - S6K. *See* Ribosomal S6 kinases
 - Satellite tobacco necrosis virus (STNV), 238
 - SBI-756, 480
 - SCA. *See* Spinocerebellar ataxia
 - Sea urchin egg, history of translational control studies, 15
 - SelB, 87–89
 - SERPINE1, 220
 - SG. *See* Stress granule
 - Shine–Dalgarno sequence, 84, 303
 - Signal recognition particle (SRP), 17
 - SILAC. *See* Stable isotope labeling with amino acids in cell culture

Index

- SINAPS, 191, 193
Sindbis virus, 446, 452
SINEB2, 220
Single-molecule fluorescence. *See* Zero-mode waveguide
SKAR, 386
SKI7, 266, 274
Smg, 413
SMG1, 288, 290
SMG5, 290–293
SMG7, 290–291
SMG8, 288
SMG9, 288
SNAIL, 382
Spinocerebellar ataxia (SCA), RAN translation, 250–251, 253
SRP. *See* Signal recognition particle
Stable isotope labeling with amino acids in cell culture (SILAC), 3
STNV. *See* Satellite tobacco necrosis virus
Stress granule (SG)
 composition, 339
 condensation, 343–344
 formation, 339–343
 overview, 337–339
 pathology, 347–348
 phase transition concept in formation, 345–347
 prospects for study, 348–349
 signaling function, 347
 translational control, 340–343
 virus response, 447
SURF complex, 288
Syk1, 482
- T**
- TASEP, 194
TASNIKS motif, 68, 75
Taura syndrome virus (TSV), 117
TC. *See* Ternary complex
TDP43, 348
TE. *See* Translation efficiency
5'-Terminal ologopyrimidine (TOP), 16, 378–380
Termination, translation
 codon recognition, 156–157
 eRF3 hydrolysis of GTP, 68–69
 overview
 eukaryotes, 65–66, 156, 284–285
 prokaryotes, 95–97
 peptide release, 70
 recycling of ribosomes. *See* Ribosome regulation
 cis-acting elements, 74–75
 nascent peptides, 75
 overview, 72–73
 posttranslational modification, 75
 stop codon readthrough therapeutic enhancement, 75
 trans-acting factors, 73–74
 ribosome profiling, 133
 stop codon readthrough, 158–159
 stop codon recognition, 67–68
 ternary complex formation, 66–67
Ternary complex (TC)
 formation, 66–67
 initiation of translation
 binding to ribosome 40S subunit, 27–29
 cancer defects, 396–397
 formation, 26–27
 imaging, 115
 preinitiation complex availability regulation, 146–147
 therapeutic targeting, 471–472
TG45BZ, 482
TGD31, 482
TGF- β . *See* Transforming growth factor β
THI4, 308
Thiamin pyrophosphate (TPP), riboswitches, 308–311
TIA-R, 379
TIA1, 338, 340, 343–344, 379
TIAR, 343, 345
Timeline, discoveries in protein synthesis and regulation, 8–12
TimeSTAMP, 189
tRNA, 343
TISU. *See* Translation initiator of short 5'UTR
TNRC6, 344
TOP. *See* 5'-Terminal ologopyrimidine
TPP. *See* Thiamin pyrophosphate
TRAF2, 347
Transfer RNA (tRNA). *See also* Ternary complex
 history of study, 13
Transforming growth factor β (TGF- β), 399
Translating ribosome affinity purification (TRAP), 134
Translation efficiency (TE), 143
Translation initiator of short 5'UTR (TISU), 241, 327
Transport/export complex (TREX), 214
TRAP. *See* Translating ribosome affinity purification
TREX. *See* Transport/export complex
TRICK, 192
TRIM32, 272
tRNA. *See* Transfer RNA
TSC proteins, 372
TSV. *See* Taura syndrome virus
TTP, 345
TURBS, 77
- U**
- UCHL1, 220
UL38, 448
Unfolded protein response (UPR), 365–366
UPF1, nonsense-mediated mRNA decay role, 74, 267
 mechanism, 288
 overview, 287–288
 phosphorylation regulation, 288
UPF2, 74, 290, 293

UPF3, 74, 290, 293

UPF3b, 67

UPR. *See* Unfolded protein response

USP10, 344

V

Vaccinia virus, 452

VACV, 455

Vanishing white matter (VWM), 364–365, 473

VEGE, 470, 474

VEGFA, 401

Viruses. *See also specific viruses*

coding and recoding strategies, 457–459

dicistrovirus internal ribosome entry site, 453

genome-wide studies

annotation, 454–455

host shut-off, 455

infected cell landscape, 455–456

synthetic genome recoding, 456

host defense, 444–445

immune evasion, 446–447

infection overview, 443–444

messenger RNA modifications, 456–457

prospects for translation studies, 459–460

ribosomal proteins, 453–454

ribosome capture

cap-independent translation, 450–452

elongation control, 452–453

m⁷GTP-capped messenger RNA

production, 452

ribosome stalling, 459

stress response and persistence, 450

translation remodeling in infected cells,
447–450

upstream open reading frames, 459

VWM. *See* Vanishing white matter

W

Wolcott–Rallison syndrome, 364

X

XIAP, 236

XRN1, 266, 268, 270, 291, 338, 344, 448

Y

Y14, 292

YBX1, 218, 272

YTHDF proteins, 456

YTHDF1, 218

YTHDF2, 203, 206–207, 240

Z

ZBP1, 191

Zero-mode waveguide (ZMW), single-molecule
fluorescence

eukaryotic translation studies, 176

fluorescence resonance energy transfer of
conformational changes during prokaryotic
translation, 171–173

historical perspective, 171

messenger RNA modification and elongation dynamics,
175

overview, 168–171

translation termination coupling with recycling in
prokaryotes, 176

translational bypassing and structural rearrangement
studies, 175–176

Zika virus, 456

ZMW. *See* Zero-mode waveguide

ZNF217, 207

ZNF609, 216

This is a free sample of content from Translation Mechanisms and Control.
[Click here](#) for more information on how to buy the book.